Literature DB >> 7909656

Takayasu arteritis.

G S Kerr1, C W Hallahan, J Giordano, R Y Leavitt, A S Fauci, M Rottem, G S Hoffman.   

Abstract

OBJECTIVE: To evaluate prospectively the clinical features, angiographic findings, and response to treatment of patients with Takayasu arteritis.
DESIGN: 60 patients with Takayasu arteritis were studied at the National Institute of Allergy and Infectious Diseases between 1970 and 1990 and were followed for 6 months to 20 years (median follow-up, 5.3 years). MEASUREMENTS: Data on clinical features, angiographic and laboratory findings, disease course, and response to therapy were all recorded and stored in a computer-based retrieval system.
SETTING: The Warren Magnuson Clinical Center of the National Institutes of Health.
RESULTS: In our series of patients, Takayasu arteritis was more common in Asian persons compared with persons from other racial groups. Females (97%) were most frequently affected. The median age at disease onset was 25 years. Juveniles had a delay in diagnosis that was about four times that of adults. The clinical presentation ranged from asymptomatic to catastrophic with stroke. The most common clinical finding was a bruit. Hypertension was most often associated with renal artery stenosis. Only 33% of all patients had systemic symptoms on presentation. Sixty-eight percent of patients had extensive vascular disease; stenotic lesions were 3.6-fold more common than were aneurysms (98% compared with 27%). The erythrocyte sedimentation rate was not a consistently reliable surrogate marker of disease activity. Surgical bypass biopsy specimens from clinically inactive patients showed histologically active disease in 44% of patients. Although clinically significant palliation usually occurred after angioplasty or bypass of severely stenotic vessels, restenosis was common. Medical therapy was required for 80% of patients, whereas 20% had monophasic self-limiting disease. Immunosuppressive treatment with glucocorticoids alone or in combination with a cytotoxic agent failed to induce remission in one fourth of patients; about half of those who achieved remission later relapsed.
CONCLUSIONS: In North America, Takayasu arteritis is a rare disease. It is heterogeneous in presentation, progression, and response to therapy. Current laboratory markers of disease activity are insufficiently reliable to guide management. Most patients require repeated and, at times, prolonged courses of therapy. Although mortality was low, substantial morbidity occurred in most patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909656     DOI: 10.7326/0003-4819-120-11-199406010-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  331 in total

Review 1.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

2.  CLINICAL PROFILE OF TAKAYASU'S ARTERITIS.

Authors:  S K Sharma; K V Sangameswaran; S P Kalra
Journal:  Med J Armed Forces India       Date:  2017-06-26

3.  Takayasu's Arteritis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

4.  The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis.

Authors:  Myles Webb; Anthony Chambers; Adil AL-Nahhas; Justin C Mason; Lucy Maudlin; Lucy Rahman; John Frank
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-17       Impact factor: 9.236

Review 5.  Takayasu arteritis: a review.

Authors:  S L Johnston; R J Lock; M M Gompels
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

6.  Detection of alterations in brain glucose metabolism by positron emission tomography in Takayasu's arteritis.

Authors:  Stefan M Weiner; Peter Vaith; Ulrich A Walker; Ingo Brink
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

7.  Non-invasive imaging in the diagnosis and management of Takayasu's arteritis.

Authors:  J Andrews; A Al-Nahhas; D J Pennell; M S Hossain; K A Davies; D O Haskard; J C Mason
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

8.  Takayasu's arteritis and hepatitis C: a new association?

Authors:  Edward B Miller; Joshua A Friedman
Journal:  Clin Rheumatol       Date:  2004-04-21       Impact factor: 2.980

Review 9.  Aneurysmatic disease in patients with Takayasu disease: a case review.

Authors:  S Perrotta; G Rådberg; A Perrotta; S Lentini
Journal:  Herz       Date:  2011-11-11       Impact factor: 1.443

10.  Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016.

Authors:  Antoine G Sreih; Fatma Alibaz-Oner; Tanaz A Kermani; Sibel Z Aydin; Peter F Cronholm; Trocon Davis; Ebony Easley; Ahmet Gul; Alfred Mahr; Carol A McAlear; Nataliya Milman; Joanna C Robson; Gunnar Tomasson; Haner Direskeneli; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.